AZN Chart

1 Month

	Date	Diff
	2025-05-02	+2.74 %
AstraZeneca (AZN) stock rose 2.74% amidst a rally in British markets driven by the U.K.'s protection from U.S. tariff issues, increased investor confidence from easing U.S.-China trade tensions, and the appeal of defensive stocks in a volatile environment. AstraZeneca's (AZN) stock rose 2.74% following the announcement of encouraging preliminary results from a clinical trial evaluating the safety and anti-tumor activity of their monoclonal antibody AMG 404, which targets PD-1 in patients with advanced solid tumors, indicating potential advances in cancer treatment that may benefit the company’s pipeline. AstraZeneca (AZN) stock rose 2.74% following an upgrade in earnings per share estimates by Leerink Partners, which increased its forecast for Q1 2025 from $1.11 to $1.13, and positive ratings from other analysts indicating a strong market outlook.
	2025-05-01	-1.78 %
AstraZeneca's stock (NASDAQ:AZN) fell by 1.78% following the announcement of disappointing quarterly revenue results that, although beating earnings per share estimates, were below analysts' expectations, which may have led to decreased investor confidence. AstraZeneca's stock (LON:AZN) declined by 1.78% despite a restated "buy" rating from analysts due to a general market correction or investor sentiment rather than any negative news specific to the company.
	2025-04-30	+0.11 %
The article discusses the upcoming Annual General Meeting of Pharming Group N.V. on June 11, 2025, where Dr. Elaine Sullivan is nominated for a new Non-Executive Director position, and the approval of various agenda items related to board appointments and auditors. The mention of AstraZeneca (AZN) stock increasing by 0.11% may be attributed to a general positive market sentiment, or specific developments related to their ongoing projects or collaborations, such as advancements in drug development or strong Q1 financial performance, which often influence stock price movements.
	2025-04-29	+2.55 %
AstraZeneca (AZN) stock rose by 2.55% despite a mixed earnings report and the cancellation of a failed cancer study due to better-than-expected earnings performance, although sales fell short of expectations. AstraZeneca (AZN) stock saw a 2.55% increase last night amidst a generally positive market sentiment driven by easing trade tensions, as investors reacted favorably to news regarding potential tariff relief for automakers, which boosted overall market confidence. AstraZeneca (AZN) stock rose 2.55% due to increased investor optimism and interest, supported by hedge funds' strong confidence in the stock's long-term growth potential following its significant institutional backing. AstraZeneca stock increased by 2.55% despite a mixed first-quarter report and a setback in its experimental prostate cancer treatment, likely driven by better-than-expected earnings results. AstraZeneca (AZN) stock rose 2.55% likely due to positive market sentiments surrounding the appointment of Dr. Jesse Hall as Chief Medical Officer at Aclaris Therapeutics, which is developing new therapies for immuno-inflammatory diseases, hinting at potential advancements in the pharmaceutical sector.
	2025-04-28	+0.52 %
AstraZeneca (AZN) stock rose by 0.52% amid overall gains in European equities, driven by increasing investor optimism about avoiding severe impacts from US tariffs and increased activity in mergers and acquisitions, alongside a notable gain in healthcare stocks. AstraZeneca's stock rose by 0.52% likely due to a reported 6.6% increase in its dividends, contributing significantly to the overall positive dividend performance of U.K. pharmaceuticals in the first quarter, which exceeded analysts' expectations. AstraZeneca (NASDAQ: AZN) stock rose by 0.52% likely in anticipation of its upcoming Q1 2025 earnings report, which analysts expect to show growth, alongside recent positive analyst ratings and a dividend increase that contributes to investor confidence. AstraZeneca (AZN) stock was up 0.52% last night, likely due to the overall market dynamics affecting healthcare stocks as investors look for stability amid trade war concerns and economic volatility favoring established firms in the sector.
	2025-04-25	+0.03 %
AstraZeneca's stock (NASDAQ: AZN) rose by 0.03% following an increase in fiscal year 2025 earnings per share estimates by analysts at Leerink Partners, who now predict earnings of $4.47 per share, slightly above previous forecasts.
	2025-04-24	+1.52 %
AstraZeneca's stock (AZN) rose 1.52% reportedly due to positive developments in the collaboration with HUTCHMED on cancer treatments, particularly the presentation of encouraging data for their MET inhibitor, savolitinib, at an upcoming major cancer conference, which may enhance investor confidence in the company's future growth and product pipeline. AstraZeneca (AZN) stock went up by 1.52% due to strong buying pressure and a technical breakout, as it successfully crossed a key resistance level and closed above its 50-day moving average, indicating positive momentum in the market. AstraZeneca (AZN) stock rose by 1.52% following an upgrade by Leerink Partners, who raised their Q4 2025 EPS estimates and overall positive sentiment from other analysts, contributing to a consensus "Buy" rating for the stock.
	2025-04-23	+0.94 %
AstraZeneca's (AZN) stock rose by 0.94% following the announcement that Ascentage Pharma's key drug candidates are set to be presented at the prestigious ASCO Annual Meeting, which may signal positive developments in cancer therapy that investors find promising for the pharmaceutical sector. AstraZeneca (AZN) stock rose by 0.94% following the announcement of a multiyear partnership with Tempus AI and Pathos AI to enhance healthcare through artificial intelligence. AstraZeneca's stock (AZN) rose by 0.94% due to its concerns over potential tariffs on pharmaceuticals amidst ongoing U.S.-China trade tensions, with the company's chairman highlighting the negative impact tariffs could have on patient health and the market's reaction to possible regulatory changes. AstraZeneca (AZN) stock experienced a 0.94% increase due to a strategic collaboration announced with Tempus AI and Pathos AI aimed at developing a multimodal project.
	2025-04-22	+1.45 %
AstraZeneca (AZN) stock rose by 1.45% following HUTCHMED's announcement of positive interim results from a Phase II clinical trial of savolitinib for treating gastric cancer with MET amplification, which has garnered Breakthrough Therapy Designation from China's NMPA, suggesting strong potential for future market approval and growth.
	2025-04-21	-1.02 %
AstraZeneca (AZN) stock fell by 1.02% due to various market factors affecting the healthcare sector, although specific reasons for the decline were not detailed in the article. AstraZeneca (AZN) experienced a decline of -1.02% in its stock, potentially influenced by the recent announcements from Ascentage Pharma regarding their inclusion of novel drugs in the 2025 Chinese Society of Clinical Oncology Guidelines, which may have shifted investor focus away from AZN.
	2025-04-17	+0.81 %
AstraZeneca (AZN) stock rose 0.81% likely due to positive developments in the weight-loss drug market, where competitor Eli Lilly's successful trial of its oral weight-loss pill put pressure on peers like AstraZeneca to innovate in the same space, increasing investor optimism about AstraZeneca's potential in the obesity drug sector.
	2025-04-15	-0.21 %
AstraZeneca (AZN) stock was down by 0.21% recently, attributed to broader market issues such as South Korea's political crisis and U.S. tariff impacts affecting investors' confidence and trading activity. AstraZeneca (AZN) stock was down by 0.21% due to overall market fluctuations, investor sentiment, or specific company-related news, though the article does not provide a detailed reason for this decline. AstraZeneca (AZN) stock decreased by 0.21% last night, as a result of potential negative investor sentiment influenced by developments in the biopharmaceutical sector, including the appointment of Dr. Leonardo Viana Nicacio at Protara Therapeutics, highlighting competition and leadership shifts in oncology that may affect market perceptions. AstraZeneca (AZN) stock experienced a slight decline of -0.21%, despite receiving a consensus rating of "Moderate Buy" from analysts, likely due to fluctuations in broader market conditions or investor sentiment.
	2025-04-14	+2.59 %
AstraZeneca (AZN) stock rose 2.59% following Pfizer's announcement of halting development of its weight-loss drug due to safety concerns, as it suggests a potential increase in demand for AstraZeneca's own weight-loss medications, positioning it favorably in the market. AstraZeneca (NASDAQ:AZN) stock rose 2.59% recently, despite a downgrade in Q4 2026 earnings estimates by Zacks Research, due to favorable ratings upgrades from several analysts and a notable increase in institutional investment, including significant stakes acquired by hedge funds. AstraZeneca's (AZN) stock rose by 2.59% due to positive developments related to its partnerships, including a significant licensing deal with the biotech firm Alteogen worth $1.4 billion, which bolstered investor confidence. AstraZeneca (AZN) stock saw a 2.59% increase, likely due to investor sentiment favoring companies with minimal exposure to China amid rising tariffs and trade tensions impacting other sectors, particularly as highlighted by Jim Cramer during a recent episode of Mad Money.
	2025-04-10	-2.83 %
AstraZeneca (AZN) stock dropped by 2.83% due to concerns over the potential for tariffs on the pharmaceutical industry, following signals from the Trump administration about upcoming trade policy actions that could impact the sector.
	2025-04-09	+2.87 %
AstraZeneca (AZN) stock rose 2.87% last night amidst a broader backdrop of declining European stock markets affected by heightened trade war tensions between the U.S. and China, which led to fears of a recession impacting most sectors, including pharmaceuticals, despite AZN itself facing downturns in recent days due to tariff concerns. The rise in AstraZeneca's stock could be attributed to a temporary rebound or positive sentiment amidst an overall negative market context, potentially due to investors seeking safe-haven stocks or reacting to specific company developments that may have outweighed broader trade war fears temporarily. AstraZeneca (AZN) stock rose by 2.87% following a consensus "Buy" rating from ten brokerages and positive updates from research analysts including UBS and Morgan Stanley, indicating growing investor confidence. AstraZeneca (AZN) stock rose 2.87% despite a general downturn in European markets, likely due to investor optimism or resilience in the pharmaceutical sector amidst broader economic fears linked to U.S. tariffs impacting other industries. AstraZeneca (AZN) stock rose by 2.87% amid a broader market rebound triggered by President Trump's announcement to pause tariffs for 90 days on certain countries, which provided some relief for investors concerned about escalating trade tensions affecting the pharmaceutical industry. AstraZeneca (AZN) stock rose 2.87% despite broader market volatility and concerns over tariffs impacting the pharmaceutical industry, likely due to investor sentiment shifting towards potential stability and opportunity in the biotech sector amidst ongoing market fluctuations.
	2025-04-07	-3.9 %
AstraZeneca (AZN) stock fell by 3.9% amid market volatility triggered by US President Donald Trump's tariff announcements, which raised concerns about potential economic downturns and inflation affecting investor sentiment. AstraZeneca (AZN) stock declined by 3.9% amidst a global stock market rout, which wiped over $10 trillion off major markets due to heightened concerns about the economic impact of U.S. tariffs introduced by President Donald Trump. AstraZeneca (AZN) stock fell by 3.9% amid broader global market turmoil triggered by fears of U.S. tariff retaliations that raised concerns over a potential economic downturn, affecting investor sentiment and market performance. AstraZeneca (AZN) stock dropped by 3.9% due to various market factors, including competitive pressures and possibly investor reactions to recent developments in drug approvals, specifically related to the approval of Osimertinib Tablets for lung cancer treatment.
	2025-04-04	-7.39 %
AstraZeneca (AZN) stock fell by 7.39% due to the negative impact of U.S. tariffs on Swedish exports, specifically amid concerns over potential retaliation and its effects on global trade that could impact growth opportunities for the company.
	2025-04-03	+2.35 %
AstraZeneca (AZN) stock rose by 2.35% likely due to the management changes at Novo Nordisk, specifically the promotion of Ludovic Helfgott, who previously handled portfolios at AstraZeneca, suggesting potential positive implications for the competitive landscape in the pharmaceutical industry. AstraZeneca (AZN) stock rose 2.35% due to positive investor sentiment following the announcement of significant developments or favorable market conditions related to its products or pipeline.
	2025-04-02	-0.52 %
AstraZeneca (AZN) stock declined by 0.52% due to economic uncertainties stemming from newly announced US tariffs, particularly potential future tariffs on pharmaceuticals, which could impact the company’s business in the EU. AstraZeneca (AZN) stock declined by 0.52% amid mixed activities from institutional investors, some of whom have recently altered their holdings, and after the company reported earnings that fell short of analysts' expectations. AstraZeneca (AZN) stock fell by 1.2% amid a broader decline in European healthcare stocks, as investors reacted to concerns over potential U.S. tariffs that could impact global economic growth and inflation.
	2025-04-01	-1.22 %
AstraZeneca (AZN) stock fell 1.22% despite a generally positive day for European markets and other healthcare stocks, likely due to broader market concerns about rising US tariffs and economic uncertainties impacting investor sentiment. AstraZeneca (AZN) stock decreased by 1.22% due to market reactions following leadership changes at Nxera Pharma, where Mr. Kiyoshi Kaneko, a former executive at AstraZeneca, was appointed as Chief Commercial Officer, potentially raising concerns about talent shifts within the industry.
	2025-03-31	-0.39 %
AstraZeneca (AZN) stock experienced a decline of -0.39% due to market reactions to various regulatory developments and acquisition announcements involving Fortress Biotech, which may have influenced investor sentiment. AstraZeneca stock experienced a decline of 0.39% despite announcing that its experimental pill effectively reduces "bad" LDL cholesterol by 51%, possibly due to market reactions to mixed investor sentiment or broader market trends impacting stock performance. The AstraZeneca (AZN) stock experienced a decline of -0.39%, likely influenced by ongoing uncertainties in the healthcare sector, particularly in the context of recent clinical trial results and market reactions to pharmaceutical developments related to heart disease treatment.
	2025-03-27	+0.17 %
AstraZeneca (AZN) stock saw a slight increase of 0.17% due to heightened logistical adjustments by pharmaceutical companies, including expedited shipments of medicines to the U.S. in response to potential impending tariffs announced by President Trump, which has raised concerns across the industry. AstraZeneca (AZN) stock increased by 0.17% due to positive developments regarding its TAGRISSO® treatment for non-small cell lung cancer, which reinforces its effectiveness and safety across various patient stages, further buoyed by the overall growth of the radiotherapy market.
	2025-03-25	-1.4 %
AstraZeneca (AZN) stock fell by 1.4% due to a combination of market volatility, tariff concerns, and overall uncertain economic conditions impacting investor sentiment. AstraZeneca (AZN) stock fell by 1.4% due to market reactions potentially influenced by external factors such as developments from competitors, like Ascentage Pharma's promising preclinical results announced ahead of the upcoming American Association of Cancer Research Annual Meeting, which could raise competitive concerns in the oncology market. AstraZeneca (AZN) stock declined by 1.4% likely due to market corrections or investors reacting to broader market trends, despite the company reporting strong financial metrics and being well-positioned technically.
	2025-03-24	-1.12 %
AstraZeneca (AZN) stock recently declined by 1.12% following its announcement of a $2.5 billion investment in a research and development center in Beijing, which caused uncertainty among investors regarding the potential risks and returns of such a substantial investment. AstraZeneca (AZN) stock fell by 1.12% despite a consensus recommendation of "Moderate Buy" from analysts, likely due to ongoing market volatility and investment sentiment, despite positive recent ratings from several banks. AstraZeneca (AZN) stock fell by 1.12% amid a broader decline in the pharmaceuticals and biotech sector, which lost 1.5% due to concerns over US tariffs and overall market volatility impacting investor sentiment.
	2025-03-20	+0.26 %
AstraZeneca (NASDAQ:AZN) stock saw a 0.26% increase due to significant increases in institutional investments, particularly by Independent Advisor Alliance and other firms, as well as a recent upgrade in ratings by analysts and an upcoming dividend payment. The AstraZeneca (AZN) stock saw a 0.26% increase due to optimistic developments in the oncology small molecule drugs market, where strategic investments and innovative treatments are expected to fuel growth, enhancing competitive advantages for leading pharmaceutical companies like AstraZeneca. AstraZeneca (AZN) stock increased by 0.26% last night, which may be attributed to positive trends in the biotechnology sector, as illustrated by competing companies like Cellectis and Achilles Therapeutics showing strong investment potential and institutional backing, which generally boosts investor sentiment towards related firms, including AstraZeneca. AstraZeneca's (AZN) stock increased by 0.26% following the announcement of promising data from HUTCHMED's SAVANNAH Phase II trial, demonstrating high and durable response rates for savolitinib combined with TAGRISSO® in treating MET-high lung cancer, which indicates a potential new effective treatment strategy in a challenging patient population.
	2025-03-18	-0.39 %
AstraZeneca (NASDAQ: AZN) stock fell by 0.39%, potentially due to mixed analyst ratings, the company's recent earnings miss, and overall market conditions affecting investor sentiment. AstraZeneca (AZN) stock decreased by 0.39% likely due to a broader market trend where international stocks have been gaining interest, while U.S. stocks, including AstraZeneca, are experiencing a downturn, reflecting changes in investor preferences towards foreign markets.
	2025-03-17	-0.3 %
AstraZeneca (AZN) stock was down by 0.3% last night, potentially due to broader market concerns regarding tariffs and economic uncertainty affecting US share markets, which may have influenced investor sentiment. AstraZeneca (AZN) stock is down by 0.3% due to the overall volatility in the stock market, which has seen significant declines across various sectors, including healthcare. AstraZeneca (AZN) stock declined by 0.3% last night, which may be attributed to a lack of specific positive news or developments impacting the company directly, as the article primarily focuses on the strong performance of Science Applications International Corp instead.
	2025-03-14	+1.42 %
AstraZeneca (AZN) stock rose 1.42% due to an upgrade in its IBD Relative Strength Rating from 80 to 83, indicating improved price performance.
	2025-03-13	+1.24 %
AstraZeneca (AZN) stock rose 1.24% due to its strong performance over the past several weeks, maintaining resilience in a declining market and approaching a potential buy point. AstraZeneca (AZN) stock rose by 1.24% due to a strategic partnership with Cellectis, which announced progress in their clinical programs, including multiple allogeneic CAR T-cell therapies, along with additional investments from AstraZeneca that enhance confidence in funding and collaboration in the biotech space.
	2025-03-12	+1.79 %
AstraZeneca (NASDAQ:AZN) stock rose by 1.79% partly due to an overall positive outlook from analysts, with an average recommendation of "Buy" and recent upgrades by firms such as UBS, indicating increasing investor confidence and potential growth in value.
	2025-03-11	-2.3 %
AstraZeneca (AZN) stock fell by 2.3% amid concerns about increasing competition in the medical devices market, highlighted by Zydus Lifesciences' announcement of its acquisition plans for Amplitude Surgical, which may signal a shift in healthcare investment dynamics that could impact pharmaceutical companies.
	2025-03-07	+0.04 %
AstraZeneca (AZN) stock was up 0.04% last night due to shareholders' positive sentiment following strong annual results for Alliance Witan PLC, which indicated solid performance, an increase in dividends for the 58th consecutive year, and a successful combination with Witan that enhanced liquidity and positioned the company favorably in the market.
	2025-03-06	-0.63 %
AstraZeneca's stock declined by 0.63%, primarily due to increasing competition from local generic drug manufacturers entering the oncology market, which is anticipated to pressure prices downward. AstraZeneca (AZN) stock experienced a decline of 0.63% due to competitive pressures from other biotech firms like 4D Molecular Therapeutics and Moderna, which may have influenced investor sentiment and market dynamics. AstraZeneca (AZN) stock fell by -0.63% due to general market trends and a cautious investor sentiment driven by broader economic concerns and geopolitical risks.
	2025-03-05	+0.92 %
AstraZeneca's stock increased by 0.92% following the announcement that Ascentage Pharma's drug olverembatinib received Breakthrough Therapy Designation in China for treating a type of leukemia, indicating strong potential for the drug and subsequent market opportunities in oncology, which could positively influence AstraZeneca's collaboration and market positioning in this therapeutic area.
	2025-03-04	+1.51 %
AstraZeneca's stock rose by 1.51% as it crossed above its 200-day moving average amidst positive analyst ratings, including an "overweight" and "buy" recommendations, indicating strong investor confidence in the company's performance.
	2025-03-03	-0.14 %
AstraZeneca (AZN) stock decreased by 0.14%, likely due to the overall poor performance and public perception issues facing the pharmaceutical industry, exacerbated by a high-profile murder within a major healthcare company and the appointment of a health secretary who is critical of big pharma advertising practices, highlighting the industry's struggles with public relations and financial profitability.
	2025-02-27	+0.17 %
AstraZeneca (AZN) stock rose by 0.17%, likely due to positive market sentiment related to its ongoing developments and effective contributions in the healthcare sector, including advancements in vaccine effectiveness reporting, which may boost investor confidence.
	2025-02-26	+0.16 %
AstraZeneca (NASDAQ:AZN) stock rose by 0.16% as the New York State Common Retirement Fund increased its stake in the company by 7.4% during the fourth quarter, reflecting growing institutional investor confidence in the stock.
	2025-02-25	+0.95 %
AstraZeneca (AZN) stock rose by 0.95% last night, reflecting positive market sentiment potentially influenced by its partnerships and developmental progress in the biotechnology space, particularly its collaborations with companies like Silence Therapeutics in advancing therapeutic innovations. The article discusses recent developments in Delaware corporate law, particularly focusing on statutory books and records demands, merger litigation, and the judicial handling of corporate governance issues. AstraZeneca (AZN) stock rose by 0.95% likely due to positive developments in the legal landscape that may enhance investor confidence, particularly in corporate governance and litigation outcomes that could favor the company. AstraZeneca (AZN) stock experienced a 0.95% increase, likely influenced by the ongoing acquisition of Bluebird Bio by Carlyle and SK Capital Partners, signaling potential growth in the gene therapy sector, amidst Pfizer's withdrawal from certain gene therapies which could create more market space for AstraZeneca's offerings.
	2025-02-24	+0.63 %
AstraZeneca (AZN) stock rose by 0.63% likely due to positive sentiment towards the growing market for photodynamic therapies in oncology, driven by increasing cancer diagnoses and advancements in treatment options, which may enhance the company's prospects in this area. AstraZeneca (AZN) stock rose by 0.63% due to potential business developments, including its collaboration with startup Koniku, which is developing innovative neuron-silicon hybrid technology for sensing applications, possibly enhancing drug testing capabilities.
	2025-02-21	+0.97 %
AstraZeneca's stock (LON:AZN) increased by 0.97% after JPMorgan and other analysts reiterated their positive ratings, reflecting strong buy sentiments and favorable forecasts for the company's performance. The rise in stock price is primarily due to the reaffirmed "overweight" and "buy" ratings from several analysts.
	2025-02-20	+1.02 %
AstraZeneca's (AZN) stock rose by 1.02% due to increased institutional investment, favorable broker ratings, and an upcoming dividend payment, reflecting growing investor confidence in the company's future performance.
	2025-02-19	-1.32 %
AstraZeneca (AZN) stock fell by 1.32% due to broader market trends affecting pharmaceutical stocks or potential negative news impacting investor sentiment, although specific reasons for its decline are not mentioned in the article. AstraZeneca (AZN) stock experienced a decline of 1.32% potentially due to unfavorable comparisons with competitors like Inovio Pharmaceuticals, which analysts favor more based on their higher target prices and stronger institutional support.
	2025-02-14	-1.17 %
AstraZeneca's stock fell by 1.17% after Leerink Partners lowered their Q1 2025 EPS estimates from $1.16 to $1.11, following a missed earnings report, which indicated weaker than expected financial performance. AstraZeneca (NASDAQ: AZN) stock fell by 1.17% following the release of quarterly earnings that missed analyst expectations, contributing to investor concerns despite institutional investors increasing their stakes in the company. AstraZeneca (AZN) stock declined by 1.17% following its earnings report that revealed it missed the consensus EPS estimate, which may have led to investor concerns despite several brokerages maintaining positive or upgraded ratings on the stock.
	2025-02-13	+0.03 %
The article discusses the comparative investment potential of Compugen and Artiva Biotherapeutics, highlighting their market positions, institutional ownership, and analyst recommendations, while noting that AstraZeneca (AZN) stock was up by 0.03%. AstraZeneca's stock could be experiencing an increase due to favorable analyst sentiment or positive developments related to its collaborations and immuno-oncology products, which often generate investor confidence. AstraZeneca (NASDAQ: AZN) stock experienced a slight increase of 0.03% due to ongoing institutional interest and a favorable shift in analyst ratings, despite the company reporting lower-than-expected quarterly earnings. AstraZeneca's (NASDAQ:AZN) stock saw a slight increase of 0.03% due to positive actions from hedge funds that adjusted their positions, upgrades from analysts, and the announcement of a higher semi-annual dividend payout. AstraZeneca's (AZN) stock increased by 0.03% last night, potentially due to favorable market conditions or positive sentiment surrounding its collaborations and developments in the biopharmaceutical sector, particularly with companies like SpringWorks Therapeutics and Innate Pharma.
	2025-02-12	+2.34 %
AstraZeneca (AZN) stock rose by 2.34% due to a combination of a recent upgrade in ratings by analysts and positive investor sentiment, despite lowered earnings estimates for FY2024. AstraZeneca (AZN) stock rose 2.34% last night, likely driven by positive investor sentiment and market conditions amidst broader financial activities and mutual fund inflows despite some volatility in the markets. AstraZeneca's stock (NASDAQ: AZN) rose by 2.34% despite a recent 15% decline over six months due to concerns arising from regulatory investigations in China, following the arrest of key executives amid allegations of illegal drug imports and insurance fraud. The uptick may be attributed to investors reacting to potential stabilizations or positive news concerning AstraZeneca's operations following the tumultuous period marked by the investigations and legal actions. AstraZeneca (AZN) stock rose by 2.34% last night, likely due to its inclusion in high-performing exchange-traded funds (ETFs) that focus on dividend yields, boosting investor interest and confidence in the stock. AstraZeneca (AZN) stock rose by 2.34% possibly due to positive market sentiment or company-specific developments that encouraged investor confidence.
	2025-02-11	+0.1 %
AstraZeneca (AZN) stock rose 0.1% amidst ongoing legal concerns and a class action lawsuit related to alleged misleading statements about the company's business operations and risks, particularly in relation to investigations in China. The stock increase may reflect a response to market fluctuations or investor sentiment despite the surrounding negative news and potential legal liabilities. AstraZeneca (AZN) stock rose by 0.1% last night likely due to positive market sentiment driven by ongoing developments in the biotechnology sector and the company’s strong fundamentals, which could include advancements in its product pipeline or favorable external conditions in the pharmaceutical market.
	2025-02-10	+0.93 %
AstraZeneca (AZN) stock increased by 0.93% following the Centers for Medicare and Medicaid Services' commitment to continue the Medicare Drug Price Negotiation Program, which may lead to more favorable pricing and negotiation strategies for pharmaceuticals. AstraZeneca's stock (NASDAQ: AZN) rose by 0.93% despite facing significant challenges and a 15% decline over the past six months due to regulatory investigations and allegations of misconduct in China, which have heightened investor concerns. The rise in AZN stock may be attributed to a market correction or a temporary recovery following heightened investor sentiment after the turbulent news surrounding the company, as well as potential positive developments or reassessments of its long-term viability amidst ongoing investigations. AstraZeneca (AZN) stock rose by 0.93% likely due to positive market sentiment following leadership changes at Cadrenal Therapeutics, where Dr. James J. Ferguson III, with significant experience including roles at AstraZeneca, was appointed Chief Medical Officer, signaling potential advancements in clinical development and strategic growth. AstraZeneca (AZN) stock was up 0.93% overnight, likely driven by investor optimism amid a generally turbulent market influenced by global trade tensions and the safe-haven appeal of certain healthcare stocks.
	2025-02-07	-0.51 %
AstraZeneca's stock (AZN) fell by 0.51% following an earnings report that showed the company missed its quarterly earnings expectation, reporting $1.05 per share instead of the anticipated $1.10. AstraZeneca (AZN) stock declined by 0.51% amid broader market trends influenced by Sanofi's announcement of a large share buyback initiative, suggesting competitive pressures in the pharmaceutical sector. AstraZeneca's stock (NASDAQ:AZN) fell by 0.51% following a disappointing quarterly earnings report that revealed earnings per share of $1.05, missing analysts' expectations of $1.10. AstraZeneca (AZN) stock decreased by 0.51% despite trading above its 200-day moving average, with various analysts maintaining a positive outlook on the company, indicating mixed investor sentiment and market fluctuations as potential reasons for the decline. AstraZeneca's stock (AZN) declined by 0.51% amid growing concerns over allegations of illegal drug imports and health insurance fraud in China, along with the further impact of regulatory scrutiny and executive detentions on the company's operational prospects in a key market.
	2025-02-06	+2 %
AstraZeneca's stock surged by 7% to 11,786 pence sterling due to a significant increase in revenues, nearly a 20% rise attributed to strong sales of its cancer treatments amid a positive sentiment in European markets fueled by robust earnings reports and optimism surrounding corporate resilience despite trade uncertainties. AstraZeneca (AZN) stock increased by 2.0% due to favorable market reactions possibly stemming from strong quarterly earnings reports and positive investor sentiment in the healthcare sector. AstraZeneca's stock rose nearly 5% due to a positive outlook following a significant increase in their annual net profit, contributing to the overall boost in the FTSE 100 index amid easing trade tensions and strong company earnings.
	2025-02-05	+2.86 %
AstraZeneca (AZN) stock rose 2.86% possibly due to market speculation or positive sentiment surrounding the company amid ongoing class action lawsuits that could alter investor perceptions and future prospects.
	2025-02-04	-1.29 %
AstraZeneca (AZN) stock dropped by 1.29% following the announcement of a class action lawsuit against the company for alleged violations of federal securities laws, including claims of insurance fraud in China and misleading statements about its business risks. AstraZeneca (AZN) stock experienced a decline of 1.29% due to market reactions that may include investors' concerns regarding the overall performance and stability of the biotechnology sector, particularly in comparison to rival companies like Innate Pharma and Agenus, along with mixed analyst evaluations and investment sentiments. AstraZeneca (AZN) stock declined by 1.29% due to the announcement of class action lawsuits alleging that the company engaged in insurance fraud in China and misrepresented its legal risks and business operations, which could have a negative impact on its business activities. AstraZeneca (AZN) stock fell by 1.29% ahead of its upcoming quarterly earnings report, likely due to investor caution and market volatility surrounding earnings expectations.
	2025-02-03	-1.27 %
AstraZeneca (AZN) stock fell by 1.27% due to allegations of engaging in insurance fraud in China, which resulted in increased legal risks and potential harm to its business operations in the region.
	2025-01-31	-0.67 %
AstraZeneca (AZN) stock declined by 0.67% following Fifth Third Bancorp's significant reduction of its stake in the company by 66.8%, indicating potential negative market sentiment among institutional investors. AstraZeneca's stock fell by 0.67% after a class action lawsuit was filed against the company for alleged securities law violations, including claims of engaging in insurance fraud in China, which has resulted in increased legal exposure and potential harm to its business. AstraZeneca (AZN) stock declined by 0.67% last night, likely due to broader market trends characterized by selling pressure and a wait-and-watch approach from investors ahead of the upcoming budget announcements.
	2025-01-30	+1.41 %
AstraZeneca (AZN) stock rose by 1.41% due to ongoing class action lawsuits related to allegations of insurance fraud and legal issues in China, raising investor attention despite the potential risks highlighted by the complaints. AstraZeneca PLC (LON:AZN) stock rose by 1.41% after receiving a consensus "Moderate Buy" rating from analysts, with strong endorsements from several brokerages, which likely contributed to positive investor sentiment. The stock's increase can be attributed to favorable analyst ratings, including "buy" recommendations and high price targets, as well as insider purchases, indicating confidence in the company's future performance. AstraZeneca (AZN) stock rose by 1.41% last night, likely influenced by positive market sentiment surrounding the upcoming 2025 budget and general economic trends that encourage investment. AstraZeneca (AZN) stock rose 1.41% amidst ongoing class action litigation related to alleged fraud and misstatements affecting the company’s operations and prospects in China, suggesting some investor confidence in a potential resolution or recovery. AstraZeneca's stock rose by 1.41% after Berenberg Bank reaffirmed a "buy" rating and set a price target, alongside positive ratings from several other analysts, indicating strong investor confidence in the company's prospects.
	2025-01-29	+0.95 %
The article mentions that AstraZeneca (AZN) stock rose 0.95%, and discusses a class action lawsuit against the company due to allegations of false statements and insurance fraud in China, leading to increased legal risks. The stock may have gone up possibly due to overall market trends, positive investor sentiment, or anticipation of resolving the legal issues without major consequences, but does not provide specific reasons for the increase in stock price. AstraZeneca (AZN) stock rose 0.95% amid ongoing concerns over a regulatory investigation in China and the arrest of an executive, although the company has faced significant setbacks, including a 15% decline over the past six months. The increase in AstraZeneca's stock price could be attributed to potential market corrections following the recent lows or a temporary positive sentiment among investors amid ongoing turmoil. AstraZeneca PLC (NASDAQ: AZN) saw a 0.95% increase in stock price as the Gross Law Firm announced a class action notice encouraging shareholders to register for potential recovery related to allegations of misleading statements and insurance fraud in China during a specific class period. The stock may have risen due to anticipation of legal clarity or shareholder interest following the law firm's outreach. AstraZeneca (AZN) stock rose by 0.95% due to positive market sentiment and expectations surrounding government policy changes that could boost investments and growth in the pharmaceutical sector.
	2025-01-28	-0.7 %
AstraZeneca (AZN) stock experienced a decline of 0.7% last night, primarily due to market fluctuations and ongoing investor sentiment influenced by broader economic factors affecting healthcare stocks.
	2025-01-27	+1.48 %
AstraZeneca (AZN) stock rose by 1.48% following promising results from a clinical trial by Fortress Biotech, Inc. for a CMV vaccine called Triplex, which may improve outcomes for transplant recipients by providing early virus-specific immunity and reducing complications associated with CMV infection. AstraZeneca's stock (AZN) rose by 1.48% as several institutional investors increased their holdings following positive quarterly earnings, improved analyst ratings, and a consensus "Buy" recommendation. The rise in stock price can be attributed to strong quarterly earnings that exceeded analyst expectations, renewed institutional interest, and upgrades from analysts which have bolstered investor confidence. AstraZeneca (AZN) stock rose by 1.48% due to positive market sentiment and potential gains in comparison to rival companies, as analysts show strong favor towards biotechnology firms such as Adlai Nortye, which indicates a favorable environment for biopharmaceutical investments.
	2025-01-24	+0.67 %
AstraZeneca's stock saw a 0.67% increase despite recent legal challenges following the filing of a class-action lawsuit alleging securities law violations regarding misleading statements about the company's operations in China, suggesting investor confidence may have been buoyed by other factors unrelated to the lawsuit. AstraZeneca (AZN) stock experienced a 0.67% increase last night despite a significant 15% decline over the past six months due to concerns regarding its operations in China and related legal issues, likely influenced by market reactions and investor sentiment stabilizing after recent negative reports. The stock's uptick may be attributed to a temporary rebound in investor confidence or market speculation, despite ongoing investigations and lawsuits related to alleged illegal drug imports and health insurance fraud affecting the company's market outlook. AstraZeneca (AZN) stock increased by 0.67% due to positive market sentiment surrounding the performance and potential of its collaborative clinical research, particularly related to its partnership with Arcus Biosciences, which is developing promising cancer therapies.
	2025-01-23	+0.59 %
AstraZeneca's stock (AZN) rose by 0.59% last night amidst news of an ongoing class action lawsuit related to prior misleading statements about the company's operations and legal troubles in China, likely indicating mixed investor sentiment following recent challenges. The stock may have gone up due to potential positive reactions from investors regarding the class action lawsuit, as it opens opportunities for some shareholders to seek recovery for losses, coupled with general market movements or external factors that provided upward pressure. AstraZeneca (AZN) stock rose by 0.59% after investment analysts at Leerink Partners increased their FY2026 earnings per share estimates for the company, indicating positive sentiment and revised expectations for its financial performance. AstraZeneca PLC (AZN) stock rose by 0.59% after institutional investors, including Ameritas Advisory Services LLC, significantly increased their stakes in the company, reflecting strong investor confidence and recent positive earnings results that exceeded market expectations. AstraZeneca (AZN) stock saw a slight increase of 0.59%, likely influenced by positive investor sentiment surrounding its recent performance and the overall positive trends in the stock market on January 23, 2025. AstraZeneca (AZN) stock increased by 0.59% following a positive sentiment from institutional investors expanding their holdings and favorable upgrades from several analysts, indicating a strong buy interest in the company.
	2025-01-22	+0.35 %
AstraZeneca (NASDAQ:AZN) stock rose by 0.35% as several institutional investors, including Brooklyn Investment Group and Merit Financial Group, significantly increased their stakes in the company during the fourth quarter, reflecting positive investor sentiment and confidence in its financial performance and growth prospects. The article discusses class action lawsuits filed against various companies, including AstraZeneca (AZN), and mentions AZN's stock was up 0.35% last night. AstraZeneca's stock may have increased due to potential investor optimism or market sentiment, despite the allegations of legal issues, as such news may not have significantly impacted investor confidence at the moment. AstraZeneca's (AZN) stock rose 0.35% despite facing a tumultuous period marked by a 15% decline over six months due to investigations by Chinese regulators into alleged illegal drug imports and health fraud, as well as the arrest of key executives, which raised concerns about its market performance in China. The stock increase may be attributed to investors reacting to potential stabilization or optimism regarding the ongoing issues or corporate communications that suggest a path forward. AstraZeneca's stock rose 0.35% last night amidst a class action lawsuit investigation regarding allegations of misleading investors about its legal risks in China, leading to heightened scrutiny but potentially stabilizing investor sentiment for the time being.
	2025-01-21	+2.04 %
AstraZeneca (AZN) stock rose by 2.04% following a consensus recommendation of "Buy" from several research firms and positive quarterly earnings results that exceeded analyst expectations, alongside increased institutional investment in the company. The stock went up due to favorable analyst ratings upgrades and strong quarterly earnings performance which indicated continued revenue growth and profitability. AstraZeneca (AZN) stock rose by 2.04% following the FDA's approval of its drug Datroway for adult patients with specific types of breast cancer who have previously received other treatments, indicating positive developments in the company's drug pipeline. AstraZeneca's stock rose 2.04% due to shareholder interest following a class action notice related to allegations of misleading statements and legal issues in China, as the firm encourages affected investors to register for potential recovery.
	2025-01-17	-0.46 %
AstraZeneca's stock (AZN) has fallen 0.46% amid concerns stemming from a wide-reaching investigation by Chinese regulators into alleged illegal drug imports and data breaches, which have prompted legal action in the U.S. and raised apprehensions about the company's market performance in China. AstraZeneca (AZN) stock experienced a decline of 0.46%, which could be attributed to market fluctuations or broader economic factors affecting investor sentiment in the pharmaceutical sector. AstraZeneca (AZN) stock declined by 0.46% following the announcement of a class action lawsuit alleging the company committed insurance fraud in China and understated its legal risks, which led to heightened legal exposure and investor losses.
	2025-01-16	+1.87 %
AstraZeneca (AZN) stock experienced a 1.87% increase likely due to positive sentiment surrounding its collaborations and clinical developments, as well as the strong performance outlook for companies in the medical sector, including those like Innate Pharma and MeiraGTx, which focus on innovative treatments.
	2025-01-15	+0.47 %
AstraZeneca's (AZN) stock increased by 0.47% recently, potentially influenced by ongoing legal issues related to allegations of insurance fraud in China that are linked to the company's exposure and operations. AstraZeneca (AZN) stock rose by 0.47% due to several hedge funds increasing their stakes in the company, indicating positive market sentiment and confidence in its financial performance, as well as strong quarterly earnings that exceeded expectations.
	2025-01-14	-0.55 %
AstraZeneca (AZN) stock declined by 0.55% following the news of a class action lawsuit alleging that the company misled investors about its legal risks and potential exposure related to insurance fraud in China, which became a significant concern after the detention of the AstraZeneca China President. The article discusses Conni Jonsson's success with EQT, Europe's largest private equity firm, highlighting its expansion and ambitions, while AstraZeneca (AZN) stock was down 0.55%, possibly due to broader market trends or specific challenges in the biopharmaceutical sector that impacted investor sentiment. AstraZeneca (AZN) stock was down by -0.55% due to market reactions following the announcement of HUTCHMED's expanded approval for its drug ORPATHYS® (savolitinib), which may heighten competition in the lung cancer treatment space where AstraZeneca is also active.
	2025-01-13	-1.91 %
AstraZeneca (AZN) stock declined by 1.91% recently, despite some institutional investors increasing their stakes and analysts generally giving it a "Buy" rating, likely due to market fluctuations and investor sentiment rather than a significant change in the company's fundamentals. AstraZeneca (AZN) stock fell by 1.91% due to significant reductions in holdings by institutional investors, including ORG Partners LLC, which lowered its position by 45.9%, signaling potential concerns about the company's future performance. AstraZeneca (AZN) stock dropped 1.91% as institutional investors adjusted their stakes, indicating fluctuations in investor confidence amidst mixed analyst ratings and recent earnings reports.
	2025-01-10	+0.65 %
AstraZeneca (NASDAQ:AZN) stock saw a 0.65% increase, partly due to significant investment growth from institutions like Fulton Bank N.A. and positive changes in analysts' ratings, indicating increased investor confidence in the company. AstraZeneca (AZN) stock was up 0.65% likely due to a market response to the recent class action lawsuit filed against the company, indicating some investor optimism despite the legal challenges and negative news surrounding alleged misconduct in China. AstraZeneca's stock price has recently increased by 0.65%, despite a significant 15% drop over the past six months, stemming from concerns about ongoing regulatory investigations in China related to illegal drug imports and health insurance fraud. The uptick in stock may be attributed to a temporary market rebound or investor optimism amidst ongoing legal challenges. AstraZeneca (NASDAQ: AZN) stock rose by 0.65% largely due to increased institutional investment interest, as indicated by First Hawaiian Bank's significant increase in its holdings and upgrades in stock ratings by research firms.
	2025-01-07	-0.3 %
AstraZeneca (AZN) stock was down 0.3% due to analysts suggesting that, despite the company's stronger revenue and earnings compared to Bionomics, a higher potential upside for Bionomics indicates it might be viewed more favorably by the market.
	2025-01-06	+0.89 %
AstraZeneca's stock has recently increased by 0.89% despite a significant 15% decline over the past six months, mainly due to ongoing legal issues and investigations related to its operations in China. The recent uptick may be attributed to a temporary recovery in investor sentiment amidst concerns over the company's ongoing exposure to regulatory risks and the impacts of a high-profile investigation involving its executive leadership. AstraZeneca (AZN) stock rose by 0.89% following the announcement that Fortress Biotech, Inc. and its subsidiary, Cyprium Therapeutics, received a Priority Review from the FDA for their drug CUTX-101, aimed at treating Menkes disease, potentially enhancing investor confidence in the company's portfolio and partnerships, including those with AstraZeneca.
	2025-01-03	+0.56 %
AstraZeneca (AZN) stock rose by 0.56% despite experiencing a 15% decline over the past six months due to ongoing regulatory investigations and legal issues in China, indicating that recent market reactions may have shifted toward a more favorable outlook or stabilization after significant declines. AstraZeneca (AZN) stock rose by 0.56% due to the FDA's recent approval of its drug Imfinzi for a new indication in treating limited-stage small cell lung cancer, expanding its market potential and reinforcing its position in the oncology sector. The article discusses a class action lawsuit filed against AstraZeneca for alleged securities law violations, which may have caused the stock to rise by 0.56% due to speculative buying amidst legal developments that could affect the company's future.
	2025-01-02	+0.55 %
AstraZeneca (AZN) stock increased by 0.55% due to positive investor sentiment likely driven by strong institutional ownership and favorable analyst recommendations in the context of comparisons with other small-cap medical companies. AstraZeneca (AZN) stock increased by 0.55% last night, likely due to positive market sentiment surrounding its collaborations and advancements in innovative therapies, particularly in immuno-oncology, as highlighted by its partnerships with companies like Cellectis. AstraZeneca (AZN) stock rose by 0.55% due to the acceptance and priority review of a New Drug Application in China for the combination of ORPATHYS® and TAGRISSO® in treating advanced lung cancer, which signifies a potential new market for their pharmaceuticals and triggers a milestone payment from AstraZeneca.
	2024-12-30	-1.04 %
AstraZeneca (NASDAQ: AZN) stock fell by 1.04% despite receiving a "Moderate Buy" rating from analysts, largely due to market fluctuations and recent changes in analyst ratings without specific negative news impacting the stock directly.
	2024-12-27	-0.39 %
AstraZeneca (AZN) stock fell by 0.39% as part of a broader decline of 15% over six months due to troubling investigations in China related to illegal drug imports and health insurance fraud, which have raised investor concerns about the company’s prospects and resulted in a class action lawsuit.
	2024-12-26	+0.33 %
AstraZeneca (AZN) stock increased by 0.33% due to the promising updates from the OlympiA Phase III trial, which showed that their drug, LYNPARZA®, significantly improved long-term survival outcomes for patients with certain types of breast cancer, indicating strong market potential in the expanding breast cancer treatment sector. AstraZeneca's stock rose by 0.33% despite facing a securities class action lawsuit alleging misrepresentation of its business practices in China, likely due to investor sentiment stabilizing after recent declines resulting from negative news about the company’s exposure to regulatory risks in the region.
	2024-12-24	-0.5 %
AstraZeneca's (AZN) stock fell by 0.5% due to the announcement of a securities class action lawsuit alleging the company engaged in insurance fraud in China, leading to increased legal risks and negative impacts on its business operations. AstraZeneca's stock fell by 0.5% after the company and Daiichi Sankyo voluntarily withdrew their application for an experimental lung cancer treatment in the EU following feedback that indicated mixed trial results did not support the drug's effectiveness across all patients. AstraZeneca (AZN) stock fell by 0.5% amid ongoing concerns related to a securities class action lawsuit in the U.S. that alleges the company misled investors about its operations in China, following damaging revelations about investigations into the company's executives and potential regulatory risks that could significantly impact revenue.
	2024-12-23	+1.96 %
AstraZeneca (AZN) stock rose 1.6% following the approval of its lung-cancer drug in the European Union, contributing to gains in the pharmaceutical and biotech sectors.
	2024-12-17	+1.43 %
AstraZeneca (AZN) stock rose by 1.43% following its advancements in the weight loss treatment market, particularly due to the promising trials of their novel oral GLP-1 receptor agonist, AZD5004, which is expected to achieve significant sales growth. AstraZeneca (AZN) stock rose by 1.43% recently, likely due to positive market sentiment regarding its collaboration with Nektar Therapeutics, which is developing promising immunotherapy treatments, enhancing investor confidence in AstraZeneca's growth potential in the biopharmaceutical sector.
	2024-12-13	-0.54 %
AstraZeneca (AZN) stock experienced a decline of 0.54%, which may be attributed to overall market trends or investor reactions to company-specific news or broader economic indicators impacting the pharmaceutical sector.
	2024-12-12	-0.68 %
AstraZeneca (AZN) stock is down -0.68% likely due to market conditions or investor sentiment influenced by the recent analysis comparing small-cap medical companies Unicycive Therapeutics and FibroGen, which may have overshadowed larger pharmaceuticals like AstraZeneca amid financial evaluations. AstraZeneca's (AZN) stock fell by 0.68% due to competitive pressure from HUTCHMED's recent announcement of Breakthrough Therapy Designation for its combination treatment involving ORPATHYS® and TAGRISSO®, which may impact the market for AstraZeneca's EGFR-targeted therapies.
	2024-12-05	+1.12 %
AstraZeneca's stock rose 1.12% following the appointment of Iskra Reic as the new head of its China operations, replacing Leon Wang, who is under investigation, which reassured investors amidst concerns stemming from Wang’s legal troubles.
	2024-12-02	-0.86 %
AstraZeneca (AZN) stock fell by 0.86% amidst mixed analyst ratings and significant trading activity among institutional investors. The decline may be contributed to recent rating adjustments and the general market volatility surrounding the biopharmaceutical sector. AstraZeneca (AZN) stock decreased by 0.86%, potentially due to comparisons with other medical companies indicating that analysts favor Ironwood Pharmaceuticals over Nuvalent, which may reflect investors' concerns about AstraZeneca's position relative to competitors. AstraZeneca (NASDAQ:AZN) shares fell by 0.86% after the Manufacturers Life Insurance Company reduced its holdings in the company by 1.0%, indicating potential investor concerns and market sentiment fluctuations impacting the stock.
	2024-11-29	+0.63 %
AstraZeneca's stock rose 0.63% likely due to strong fundamentals indicating higher revenue and earnings compared to its competitor, Revance Therapeutics, alongside favorable analyst recommendations that suggest a solid market position.
	2024-11-27	+1.27 %
AstraZeneca (AZN) stock rose 1.27% following strong third-quarter earnings that exceeded analyst expectations, along with increased institutional investments in the company. AstraZeneca (AZN) stock rose by 1.27% following the approval from India's CDSCO to import its cancer drug Lynparza, indicating positive momentum for the company's pharmaceutical developments. The article discusses Charles Schwab's diverse selection of mutual funds as attractive investment options, emphasizing their low costs and quality, and does not specifically address AstraZeneca (AZN) stock. The rise of AstraZeneca (AZN) stock by 1.27% could be attributed to various factors, including positive market sentiment, favorable clinical trial results, or developments related to the company's drug pipeline, although these specifics are not mentioned in the article.
	2024-11-26	-0.06 %
AstraZeneca (AZN) stock slightly declined by -0.06% due to factors like market volatility or investor sentiment, although the specific reasons for the decline were not detailed in the article. AstraZeneca (AZN) stock decreased by 0.06%, and the decline may be attributed to a broader trend of mixed performance in the stock market, with among other stocks, significant losses seen in key players and fluctuations in investor sentiment.
	2024-11-25	+1.17 %
AstraZeneca (AZN) stock rose by 1.17% following JPMorgan Chase's reaffirmation of an overweight rating with a target price of £140 ($176.30), amid a generally positive outlook from several analysts regarding its potential. The article discusses a comparison between two small-cap medical companies, Tectonic Therapeutic and Cellectis, highlighting their financial metrics and analyst recommendations, but does not directly address AstraZeneca's (AZN) stock performance; however, it may have gained 1.17% due to positive investor sentiment or developments related to its collaboration with Cellectis in gene therapy.
	2024-11-22	+2.13 %
AstraZeneca (AZN) stock rose by 2.13% following an insider purchase of 1,500 shares by Tony Mok at a price of £126.80 per share, indicating confidence in the company's future performance.
	2024-11-21	+1.68 %
AstraZeneca (AZN) stock rose 1.68% amid a broader rally in European markets driven by rising oil prices from geopolitical tensions, a weakening sterling boosting dollar-earning firms, and positive earnings forecasts from tech companies. The increase in AstraZeneca's stock is attributed to its status as an international, dollar-earning company benefitting from the depreciation of the British pound against the dollar. AstraZeneca PLC (LON:AZN) stock rose 1.68% as multiple brokerages issued positive ratings, with six analysts recommending a buy, reflecting investor confidence in the company's growth potential and performance. AstraZeneca (AZN) stock rose 1.68% after the company reported better-than-expected quarterly earnings of $1.04 per share and revenue of $13.57 billion, exceeding analysts' estimates, despite a downgrade in FY2025 earnings estimates from Leerink Partners.
	2024-11-20	-0.94 %
AstraZeneca (AZN) stock fell by 0.94% due to general market conditions and potential investor concerns about its ongoing collaborations and product pipelines as compared to its competitors like Voyager Therapeutics and Gritstone bio. AstraZeneca's (AZN) stock declined by 0.94% due to overall market factors influencing investor sentiment in the biopharmaceutical sector, as highlighted by contrasting investment comparisons between Qualigen Therapeutics and Ionis Pharmaceuticals, with analysts favoring Ionis based on its stronger potential upside and institutional ownership.
	2024-11-19	+0.65 %
AstraZeneca (AZN) stock rose by 0.65% amid positive market sentiment, potentially linked to strong performance indicators and favorable comparisons with other biotech firms like Innate Pharma and Avalon GloboCare, particularly in terms of revenue and earnings prospects. AstraZeneca (AZN) stock increased by 0.65% due to significant institutional investment interest, demonstrated by an increase in stakes from multiple hedge funds, bolstered by positive earnings results that exceeded analyst expectations. AstraZeneca (AZN) stock rose by 0.65% after a wider market rebound due to increased value-buying amid a rally in blue-chip stocks, especially following a period of decline in equity benchmarks.
	2024-11-18	+0.25 %
AstraZeneca (NASDAQ: AZN) stock rose by 0.25% following an increase in institutional investments, with Oppenheimer & Co. significantly boosting its position in the company and positive earnings results that surpassed analyst expectations. The stock went up due to heightened institutional buying, including significant acquisitions by Oppenheimer and other firms, as well as favorable earnings performance, which reported earnings per share above estimates and strong revenue growth year-over-year. The article discusses a comparison between Cyclacel Pharmaceuticals and Ovid Therapeutics, indicating that Cyclacel has higher earnings potential but lower revenue, while Ovid is viewed as more affordable based on its lower price-to-earnings ratio. AstraZeneca (AZN) stock's increase of 0.25% could be related to investor sentiment towards its collaborations in the biopharmaceutical sector, such as its partnerships with Ovid Therapeutics, especially considering advancements in clinical trials for neurological drugs.
	2024-11-15	-2.78 %
AstraZeneca Pharma India's Q2 2024 results showed significant revenue growth of 31.16% year-over-year to ₹408 crore, but a notable profit decline of 26.62% to ₹38.43 crore, primarily due to increased administrative expenses, leading to a -2.78% drop in its stock price. The stock decline can be attributed to the disappointing profit performance despite rising revenues, raising concerns among investors about the company's cost management. AstraZeneca (AZN) stock fell by 2.78% due to concerns in the healthcare sector following Robert F. Kennedy Jr.'s nomination as Secretary of Health and Human Services, given his controversial anti-vaccine stance and history of promoting misinformation about vaccines. AstraZeneca (NASDAQ: AZN) stock fell by 2.78% after recently announcing its earnings, despite exceeding earnings expectations, possibly impacted by mixed investor sentiment and broader market conditions. AstraZeneca's stock fell by 2.78% after Donald Trump appointed vaccine critic Robert F. Kennedy Jr., leading to concerns among investors about the potential impact on major pharmaceutical companies including AstraZeneca, Moderna, and GSK.
	2024-11-14	-0.38 %
AstraZeneca (AZN) stock has decreased by -0.38% last night due to slowing growth in its previously expanding China business amid an ongoing probe that has negatively impacted the pharmaceutical company's share price.
	2024-11-13	+0.15 %
AstraZeneca (AZN) stock rose by 0.15% amid broader market declines influenced by inflation concerns and foreign investor outflows, likely due to investors seeking relative stability in the pharmaceutical sector as other markets faced pressures. AstraZeneca (AZN) stock increased by 0.15% due to significant institutional investment activity, including new positions and increased holdings by various funds, along with favorable ratings and target price boosts from multiple research analysts. The article mentions that AstraZeneca (AZN) stock increased by 0.15% last night, although it does not provide specific reasons for this uptick; generally, stock prices can rise due to factors such as positive company news, favorable market conditions, or investor sentiment. AstraZeneca (AZN) stock rose by 0.15% amid overall market declines due to rising inflation concerns and foreign investor outflows, likely benefiting from company-specific developments or investor interest that remained positive despite broader market pressures. The stock may have gone up due to factors such as positive news about product developments, strong earnings reports, or ongoing interest in healthcare stocks in light of market volatility.
	2024-11-12	+0.62 %
AstraZeneca (AZN) stock increased by 0.62% due to institutional investors, such as Mesirow Financial, increasing their positions in the company, which reflects growing confidence and positive sentiment in AstraZeneca's prospects. AstraZeneca (AZN) stock increased by 0.62% last night amid broader market declines, likely due to investor interest in the pharmaceutical sector as companies like this continue to show resilience and potential growth despite overall market pressures. This rise can be attributed to specific investor sentiment favoring pharmaceutical stocks, which may be viewed as safer investments during market downturns or due to positive developments in the company's product pipeline or overall industry trends. AstraZeneca (AZN) stock rose by 0.62% amid a generally declining market characterized by foreign fund outflows and weak global trends, likely due to positive investor sentiment following developments in the biotechnology sector or company-specific news that may have bolstered confidence in its growth prospects.
	2024-11-11	+0.47 %
AstraZeneca (AZN) stock rose by 0.47% after JPMorgan reaffirmed its overweight rating with a price target of £140, alongside positive endorsements from other brokerages, reflecting strong confidence in the company's performance. The stock's increase can be attributed to favorable analyst ratings and price targets from multiple financial institutions, suggesting strong market confidence in AstraZeneca's future growth potential. AstraZeneca (NASDAQ: AZN) stock rose by 0.47% as it prepares to announce its quarterly earnings, with analysts anticipating earnings of $1.02 per share, while recent analyst upgrades and positive ratings have also contributed to investor confidence. AstraZeneca (AZN) stock rose 0.47% as several hedge funds increased their stakes, with positive ratings adjustments from analysts indicating growing confidence in the company's prospects. AstraZeneca's stock (LON:AZN) rose by 0.47% following Shore Capital's reaffirmation of its buy rating, among other positive endorsements from several analysts, suggesting strong market confidence in the company's performance and prospects. AstraZeneca PLC (NASDAQ: AZN) stock rose 0.47% due to increased institutional investment, with firms like Assetmark Inc. growing their positions significantly, alongside positive analyst upgrades and strong market performance indicators.
	2024-11-08	-0.31 %
AstraZeneca (AZN) stock declined by 0.31% amid varied activity from institutional investors, including a 3.7% reduction in stake from Farther Finance Advisors LLC during the third quarter. The decline could be attributed to recent selling by some institutional investors and potential shifts in market sentiment following mixed analyst ratings and target price adjustments.
	2024-11-06	-3.65 %
AstraZeneca (AZN) stock fell by 3.65% due to mixed analyst ratings following a series of upgrades and downgrades, with Deutsche Bank's downgrade to a "sell" likely contributing to investor concerns.
	2024-11-05	-7.22 %
AstraZeneca (AZN) stock fell by 7.22% due to concerns over potential tariff revisions affecting Indian generic drug exports to the US, which could negatively impact the pharmaceutical sector. AstraZeneca (AZN) stock fell by 7.22% following the detention of five employees by Chinese authorities amid an investigation into possible illegal activities and data privacy breaches in the pharmaceutical sector. AstraZeneca (AZN) stock plunged 8.4% due to escalating concerns over a Chinese investigation into the company's sales practices, which has resulted in the scrutiny of its local president and has raised fears about the impact on its operations and revenue in China.
	2024-11-04	+0.01 %
AstraZeneca (AZN) stock was up 0.01% after reports of various institutional investors adjusting their holdings, with TD Cowen raising its price target and maintaining a "buy" rating, which likely contributed to investor confidence.

1
500 / page